-
03-12-2020, 01:38 PM
#18731
Being touted by Jardens, the same crowd, along with the other 4 who picked ATM to be in the top5 performers for the year.
Be afraid, or very wary at least...
-
03-12-2020, 01:46 PM
#18732
What utter crap, nothing in common except Jarden and I would say that different analyst does PEB and ATM.
-
03-12-2020, 01:52 PM
#18733
Originally Posted by drcjp
Otago has bugger all say anymore. They are a very minor shareholder.
As for biotech buy outs, a general rule of thumb is 4-5x gross turnover. That would be 4.5B by 2030 numbers...........LOL thats not going to happen.
I would anticipate somewhere around 500M for this asset which means PE need to be turning over 130-150M (150,000-160,000 tests p.a.).....within 2-3yrs to justify the patent runout time
An interested bystander has suggested that this may be helpful.
From the Company website:
Pacific Edge also has immediate and perpetual access to any cancer intellectual property emerging from the University of Otago’s Cancer Genetics Laboratory. This relationship has been in place from when Pacific Edge was formed in 2001. This represents a significant future asset.
-
03-12-2020, 01:59 PM
#18734
Originally Posted by Greekwatchdog
What utter crap, nothing in common except Jarden and I would say that different analyst does PEB and ATM.
???, excuse me?
5 brokers who tipped ATM to be top 5 for 2020 were Jardens, Hobson, Craigs, Forbar, & HHG.
The point is they can be fallible.
-
03-12-2020, 02:03 PM
#18735
Yes like all of us. No one is walking on water. If you trust the Analysts then thats your problem. Besides ATM issues are External with the crap going on between Aust and China and Supply Issues caused by Melbourne lock down.
Back to PEB, go you good thing.
-
03-12-2020, 07:04 PM
#18736
On my rounds and just a little behind..
Originally Posted by Minerbarejet
An interested bystander has suggested that this may be helpful.
From the Company website:
Pacific Edge also has immediate and perpetual access to any cancer intellectual property emerging from the University of Otago’s Cancer Genetics Laboratory. This relationship has been in place from when Pacific Edge was formed in 2001. This represents a significant future asset.
Access is not ownership. There is a BIG difference.
-
03-12-2020, 07:15 PM
#18737
Originally Posted by drcjp
Access is not ownership. There is a BIG difference.
From experience with other universities in NZ, access to IP can also be very costly.
-
04-12-2020, 11:12 AM
#18738
Can some one get rid of the 915860 shares at $80 cents =))) . Then we are up to the moon
-
04-12-2020, 11:15 AM
#18739
Member
Originally Posted by tomm
Can some one get rid of the 915860 shares at $80 cents =))) . Then we are up to the moon
Lol! that will most likely be wiped out by the end of the day.
-
04-12-2020, 11:31 AM
#18740
Originally Posted by calledone
Lol! that will most likely be wiped out by the end of the day.
If this happen, : ==========> "THE EAGLE HAS LANDED"
I REPEAT : "THE EAGLE HAS LANDED"
but not anytime soon
Last edited by tomm; 04-12-2020 at 11:32 AM.
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks